Table 4.
Clinical trials showing treatment of ovarian cancer with anti-LAG-3 antibodies (https://clinicaltrials.gov/, accessed on 27 September 2022).
| Drug Name | Drug Type | Combination Agents | Phase | Clinical Trial Number | Status |
|---|---|---|---|---|---|
| Relatlimab | anti-LAG-3 | Ipilimumab, Cyclophosphamid, Fludarabine Phosphate, Tumor Infiltrating Lymphocytes infusion, Nivolumab | I, II | NCT04611126 | Recruiting |
| Tebotelimab | bispecific: anti-PD-1 and anti-LAG-3 | Margetuximab | I | NCT03219268 | Active, not recruiting |
| INCAGN02385 | anti-LAG-3 | - | I | NCT03538028 | Completed |
| Relatlimab | anti-LAG-3 | Adavosertib, Afatinib, Afatinib Dimaleate, Binimetinib, Capivasertib, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Larotrectinib Sulfate, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab Emtansine, Ulixertinib, Vismodegib | II | NCT02465060 | Recruiting |
| XmAb®®22841 | bispecific: anti-CTLA-4 and anti-LAG-3 | Pembrolizumab | I | NCT03849469 | Active, not recruiting |
| LAG525 | anti-LAG-3 | PDR001 | II | NCT03365791 | Completed |